Context: Pegvisomant is an effective treatment for somatostatin analogue-resistant acromegaly, but the determinants defining the response to this treatment are largely unknown. Objective: To investigate the efficacy of pegvisomant treatment in resistant acromegalic patients (e.g. serum IGF1 at least 1.25!upper normal limit) in a clinical setting and the factors conditioning this response. Design and setting: A retrospective cross-sectional study performed in six Spanish University hospitals from 2004 to 2007. Patients: Forty-four acromegalic patients (61.4% female, mean age: 49G14), 95% of whom had undergone pituitary surgery and 61% having received pituitary radiotherapy. The mean follow-up was 22.7G11.2 months. Main outcome measures: IGF1 levels reflected treatment efficacy, and the influence of gender, age, weight, previous radiotherapy and duration of treatment was assessed. Results: IGF1 normalisation was achieved in 84% of the patients. Male gender (P!0.05), previous irradiation (P!0.05) and the treatment duration (rZ0.364, P!0.02) were associated with a better response to pegvisomant therapy. There was a significant decrease in HbA1c (P!0.001) and in the mean insulin dose (P!0.01) in acromegalic diabetic patients. Although 25% of patients experienced mild adverse events, pegvisomant was only withdrawn in four patients due to side effects (two cases of tumour growth, one liver dysfunction and one headache). Conclusions: Long-term pegvisomant is a very effective therapy in resistant acromegaly. Male gender and prior radiotherapy influence the therapeutic response rate.
Introduction
There is currently much discussion about the clinical management of acromegaly as optimal therapy reverses the increased mortality associated with acromegaly (1) . Although transsphenoidal surgery is still the treatment of choice, only 60% of patients achieve adequate biochemical control with this approach, and this figure drops even further in patients with larger tumours (2, 3) . The efficacy of radiotherapy is limited due to the delay in its effect, its unpredictability and the high incidence of panhypopituitarism or other side effects. Therefore, medical therapy still plays an important role in controlling acromegaly (4) . Dopamine agonist and somatostatin analogues (SSA) exert a direct inhibitory effect on somatotropic tumours, suppressing GH secretion and in some cases, decreasing tumour size. The most potent dopamine agonists are less effective than other therapies (3) (4) (5) , and SSA only normalise insulin-like growth factor-1 (IGF1) levels in approximately two-thirds of patients with acromegaly (6) . Thus, at least one-third of patients are not controlled by these treatments (3, 4) .
The most recent medical advance in the treatment of acromegaly has involved the use of the GH receptor antagonist, pegvisomant (PEG). PEG is a bioengineered analogue of human GH that binds to the GH receptor, blocking its biological activity and inhibiting IGF1 production (7) . PEG treatment has been reported to normalise IGF1 levels in more than 90% of acromegalic patients (8) and gender, body weight, prior radiotherapy, and baseline GH and IGF1 appear to influence the doses of PEG required to normalise serum IGF1 (9) . However, the efficacy of PEG in acromegalic patients resistant to other pharmacological and non-pharmacological treatments has not been well characterised, and variable response rates to this therapy have been reported (10) (11) (12) (13) . Furthermore, the determinants underlying this variation in response have not yet been studied in a clinical practice setting (11, 14) .
Thus, we have studied the long-term data on the efficacy of PEG monotherapy in a large group of acromegalic patients resistant to different treatment modalities in a clinical setting. Possible determinants of the response to PEG therapy, including gender, age, disease activity, tumour diameter, previous pituitary radiotherapy and baseline GH and IGF1 levels were investigated. In addition, data on the metabolic effects of PEG are also presented.
Patients and methods

Patients
From February 2004, when PEG became commercially available in Spain, until December 2007, 44 patients from six university referral hospitals in Spain were included in this retrospective study. Informed consent was obtained from all the patients prior to their inclusion in the study. The patient's demographic characteristics and the treatments they received for acromegaly before the onset of the PEG therapy were recorded ( Table 1 ). The mean age of the patients was 49G14 years (range 14-79) and the gender ratio was 39% male to 61% female. All but two patients had undergone surgery, while seven patients (16%) had undergone two interventions and one patient three interventions. Of these 50 procedures, 44 were transsphenoidal procedures (88%) and 6 involved transfrontal surgery (12%). Two patients had not undergone surgery, one because the tumour was not visible by magnetic resonance imaging and the other patient refused treatment. Twenty-seven patients (61%) received external beam pituitary irradiation in addition to pituitary surgery (12 female patients and 15 male patients), whereby 15 patients received conventional radiotherapy, 10 stereotaxic fractionated radiotherapy, and two radiosurgery. The mean interval between radiotherapy and the start of PEG therapy was 4.1G 5.7 years (range 1-25 years). Finally, 14 patients (32%) had undergone radiotherapy less than 4 years before starting PEG therapy.
After more than 12 months of treatment with SSA (octreotide-LAR 30 mg/month or lanreotide autogel 120 mg/month, 21 and 23 patients respectively), the condition was not adequately controlled in any patient in accordance with recent guidelines (15) . In addition, 23 patients (52%) also received cabergoline. The inclusion criteria for PEG therapy was IGF1 levels higher than 1.25-fold the individual upper limit of normal (ULN) after at least 12 months treatment with SSA. At the beginning of PEG therapy, baseline GH and IGF1 was measured through the usual clinical procedures, 4 weeks after the last dose of SSA and 2 weeks after the last dose of the dopamine agonist.
Pegvisomant treatment
Patients were treated in all six participating hospitals according to the approved use of PEG in Spain. PEG monotherapy was initiated by daily s.c. injection of 10 mg PEG at least 1 month after the previous SSA injection. No loading dose was used. Every 2-3 months, the dose was reevaluated and titrated in 5 mg/day increments or decrements to maintain the IGF1 concentration below the ULN range of each laboratory. If IGF1 fell into the lowest quartile of the normal range, the PEG dose was reduced. All patients received PEG daily. Follow-up visits were performed every 3 months until normal IGF1 levels were reached and then every 6 months. Efficacy was assessed at the last follow-up visit.
Methods
Random GH and IGF1 serum levels were measured in hospital laboratories and interpreted according to the There were no changes in the assays or in the reference ranges in any of the hospitals during the study period. All serum samples were obtained after overnight fasting. Safety was assessed by monitoring the serum concentrations of alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), g-glutamyltranspeptidase (g-GT), lactate dehydrogenase, total bilirubin and creatinine. Serum glucose and glycated haemoglobin A 1 c (HbA 1 c) levels were also studied.
The same protocol for magnetic resonance imaging (MRI) was used and pituitary maximal tumour diameters were assessed by a single neuroradiologist at each hospital. In addition, there was a single referral neuroradiologist who reevaluated the tumour volume in all conflicting images. The MRI obtained at the baseline visit before PEG treatment and those obtained at the cut-off date for the analysis were compared and assessed. Tumour volume was calculated by the Di Chiro and Nelson formula (volume Z height ! length ! width ! p/6) (16, 17). Accordingly, significant tumour growth was considered as an increase in basal tumour volume more than 20% in tumours with a volume of 1 cc or larger, and a change of at least 3 mm in one diameter in tumours of less than 1 cc (18) . In cases where the tumour grew during PEG therapy, all MRI that were available from before and during the SSA therapy were also reevaluated.
Statistical analysis
The data are shown as the meanGS.D. (range), as raw data or as percentages where appropriate. For continuous variables, normality was assessed with the Kolmogorov-Smirnov test and logarithmic transformations were applied as necessary to ensure a normal distribution. The differences in the continuous variables depending on gender and the administration of radiotherapy were evaluated with the unpaired t-test. For discontinuous variables, the c 2 test or Fisher's exact probability test was applied, as appropriate. The relationship between the continuous variables was assessed with Pearson's test and using a partial correlation analysis to control for confounding factors.
Due to the significant relationship between the months of PEG treatment, PEG dose and normalisation of IGF1 levels, and given the possible influence of gender and radiotherapy on these variables, we performed an analysis of covariance using a multivariate general linear model (MANCOVA). In this model, normalised IGF1 levels at the end of the study were weight corrected for the PEG dose and introduced as dependent variables. Gender and radiotherapy administration were introduced as fixed factors, and the months of treatment were assessed as a covariate, evaluating their influence on continuous variables. The changes observed in IGF1 between each visit, those in HbA1c and the mean insulin dose from the baseline to the last follow-up visit, were analysed with a paired t-test, with Bonferroni's correction for multiple comparisons. All analyses were performed using SPSS 13 for Windows (SPSS Inc., Chicago, IL, USA) and P!0.05 was considered statistically significant.
Results
Efficacy
There were 44 patients with acromegaly that participated in this study. The mean follow-up time was 22.7G11.2 months, and 37 (84%) were followed up for 18 months, 30 (68%) for 24 months and 21 (48%) were followed up for more than 30 months (Fig. 1) . The normalisation of serum IGF1 was achieved in 37 patients (84%) and if we exclude, from the final efficacy analysis, two patients who were withdrawn before achieving the maximal therapeutic dose, IGF1 levels were normalised by PEG administration in 37 out of 42 (88%) of our patients. The mean maximal PEG dose used was 17G7 mg/day (0.21G0.088 mg/kg body weight) and IGF1 decreased progressively at each visit during the follow-up period, probably reflecting the dose titration effect. The decrease in IGF1 from a baseline of Seven patients were not controlled by the treatment, which was withdrawn before the maximum doses were achieved in two cases. The other five patients all were female, two had received radiotherapy and only three had reached a daily dose above 20 mg. In these latter three patients, the maximum dose of PEG per kg weight was significantly higher (0.32-0.20 mg/kg weight, P!0.05), and the mean decrease in IGF1 was significantly lower (37% as opposed to 65.8%, P!0.01) than in the patients whose condition was controlled. No statistical differences were found between these five uncured female patients and the other female patients in terms of any of the parameters analysed ( Table 2 ).
Response to therapy and gender
The clinical and biochemical characteristics of the patients are presented according to gender (Table 3 ). The baseline characteristics were similar apart from a significant difference in body weight between the male and female groups (PZ0.025). The mean change in IGF1 from the baseline to the last follow-up visit was greater in male patients than in female patients (K70G 7 and K53G21% respectively, P!0.01; Fig. 2A) , and the final mean IGF1 concentrations were also lower in male than in female patients (66G19% and 96G49% respectively, PZ0.02). In addition, the condition was controlled in a higher proportion of male patients (100% in males and 74% in females). Finally, the mean absolute dose (17G7 mg/day male and 16G8 mg/day in female patients respectively) as well as a mean weight-corrected dose of PEG (0.19 mg/kg in male and 0.24 mg/kg in female patients) was not significantly different for either group (Table 3) . Indeed, these changes persisted when adjusted in the multiple regression analysis for age, baseline GH and IGF1, PEG dose and previous radiotherapy.
Response to PEG therapy and previous radiotherapy
There were no significant differences in the baseline characteristics between those patients treated with radiotherapy and those who had not received radiotherapy ( Table 4 ). The mean decrease in IGF1 from the baseline to the last follow-up visit was greater in irradiated patients (K65G18% irradiated versus K53G19% in non-irradiated, PZ0.038; Fig. 2B ), and these changes persisted when adjusted in the multiple regression analysis for gender, age, baseline GH and IGF1 and PEG dose. Although there was a tendency to require a higher PEG dose per kg of weight to reach normal IGF1 levels in non-irradiated patients when compared with irradiated patients (0.24 and 0.19 mg/kg respectively), this difference was not statistically significant (PZ0.078). In addition, whereas none of the irradiated patients required an increase in the PEG dose after reaching normal serum levels of IGF1, 5 out of the 27 non-irradiated patients required a further increase in the dose of PEG after reaching a steady dose that normalised IGF1 at month 9G3 (PZ0.02). Moreover, the maximum PEG dose was significantly higher in these 5 patients than in the other 39 patients (0.34 compared with 0.19 mg/kg body weight; P!0.01). Although we did not measure the serum PEG concentrations during the PEG therapy, the assay used to measure the GH levels cross-reacts with PEG, and there was an increase from the baseline values that would suggest adequate compliance. Tumour progression was observed only in one of these patients.
Metabolic control in patients with diabetes
There were 13 diabetic patients (29%) in the study, all of whom experienced a significant decrease in HbA1c after PEG therapy from a mean of 8.5G2.2 to 6.3G1.4% (PZ0.001). In the five patients who continued on insulin therapy, the mean insulin dose decreased significantly and markedly from 48 U per day at the initiation of PEG to 21 U per day during PEG therapy (PZ0.008; Table 5 ).
Adverse events, progression in tumour size and treatment withdrawal
Adverse events were reported in 11 out of the 44 patients (25%). While one patient suffered a mild, erythematous, self-limited, injection-site reaction that disappeared spontaneously, three patients (7%) developed lipohypertrophy at the injection site (19) that disappeared after rotating the injection sites. Two patients complained of headaches (5%) that led to PEG withdrawal in one patient. Both suffered from headaches that had improved on administration of SSA and that relapsed after SSA withdrawal. There was no change in tumour volume in either of these patients during the period of PEG administration. Abnormal liver function was evident in two patients (4, 5%), reaching more than threefold the ULN for ALT and/or AST, and as Baseline characteristics among radiotherapy groups were assessed by unpaired t-, c 2 and Fisher's exact probability tests. a Data are showed as meanGS.D.
such the treatment was discontinued in one of them (data not shown). There was a significant progression in tumour size in three patients between months 15 and 25 after the start of PEG therapy (medianZ18.7 months). In two of these cases, the tumour progression corresponded to the growth of a post-surgical remnant, while in the other case, a microadenoma that was not detected prior to initiation of PEG was identified. None of these three patients had a tumour response during SSA therapy and PEG was withdrawn in two out of these three cases. Thus, PEG was withdrawn due to adverse events in 4 out of the 44 (9%) patients, in two of which the treatment was discontinued at months 3 and 9, before reaching the maximal effective dose for IGF1 control. In addition, there was one case of voluntary withdrawal.
Discussion
The main observation from this study is that after a mean follow-up of 23G11 months, PEG administration normalised IGF1 levels in 37 out of 44 acromegalic patients (84%) whose disease was resistant to other medical therapies, including long-term treatment with high doses of long-acting SSAs. The control of IGF1 reached 88% when the two patients who were withdrawn before receiving the maximum therapeutic dose were excluded from the final efficacy analysis. A better response to PEG therapy was associated to male gender and previous irradiation.
Data on PEG efficacy as a single agent have been obtained from three large studies, as well as from some additional smaller studies. In a 12-week placebocontrolled study with daily injections of PEG, IGF1 was normalised in 82% of patients at the end of the study (20) . In another study, IGF1 normalisation was reported in 97% of acromegalic patients treated for 12 months with PEG (8) . However, only a few small studies, involving a total of 27 patients and with a maximal follow-up of 12 months, have reported the efficacy of PEG in the subgroup of acromegalic patients resistant to SSA, demonstrating IGF1 normalisation in the range of 75-100% (10) (11) (12) (13) . In addition, the German Pegvisomant Observational Study (14) , a multicentre surveillance study with a 2-year follow-up of PEG treatment in 229 patients (78% resistant to SSA), reported normalisation of IGF1 concentrations in 71% of 102 patients after 12 months and in 76% of 39 patients after 24 months. The authors explained that their lower normalisation rates when compared with previous studies might be due to a less strict surveillance in clinical practice field conditions, and that dose titration was not completed in a significant number of patients (14) . However, although our data were also generated under clinical practice conditions, the IGF1 normalisation rates reported here were higher than in the German study. This difference could be explained through the more closely monitoring of our patients and the fact that maximal dose titration was achieved in the majority of patients. The mean PEG dose used in our study to normalise IGF1 was 17G7 mg/daily, lower than that reported in initial studies (8) and slightly higher than that used in the German Observational Study (14) .
In a previous retrospective multicentre, open-label trial study, sex, body weight, prior use of radiotherapy and baseline GH/IGF1 were found to influence the dose of PEG required to normalise serum IGF1 in a research setting (9) . We wanted to confirm these data in clinical practice including only acromegalic patients resistant to other therapies. We also found that patients treated with pituitary irradiation experienced a greater decline in IGF1 levels, as well as a tendency towards requiring a higher dose of PEG than non-irradiated patients, although this tendency did not reach statistical significance possibly due to a lack a statistical power in our study.
The response to PEG was maintained throughout the duration of the study in the majority of patients, except for five non-irradiated patients in which increments in the dose of PEG were required after a period of stable control. This phenomenon could be explained by the progressive clearance of somatostatin analogues in the first 4 months after the initiation of PEG treatment (14, 21) , a further rise in GH secondary to the fall in IGF1 (8), progressive disease/tumour progression and lipohypertrophy (19) . The progressive clearance of somatostatin analogues after the initiation of PEG treatment (14, 21) was not the explanation for this escape phenomenon in our patients, as it appeared long after completion of the SSA treatment. In addition, since serum PEG concentrations were not measured during the PEG therapy, the possibility of defective patient compliance cannot be ruled out.
One may postulate that as radiotherapy decreases the number and amplitude of GH pulses (22) , it may attenuate the expected increase in pulsatile and nonpulsatile GH levels that have been reported during PEG treatment (9, 23) , thereby preventing the escape phenomenon. Unfortunately, the assays used in this study to measure GH cross-react with PEG, and they were unsuitable to evaluate GH levels in a setting of PEG treatment (24) . Further studies with repeated measurements of GH over 24 h will be useful to interpret these results (9) . In the present study, gender also influenced the response to PEG therapy as males experienced a stronger decrease in IGF1 from the baseline to last follow-up visit, as well as having lower final mean IGF1 concentrations and a higher percentage of normalised IGF1. However, the mean weight-corrected PEG dose required was not significantly different in male and female patients. In a previous study, while males displayed a significantly stronger decrease in IGF1, no differences in the final IGF1 levels were seen when compared with female patients, even though a 20% higher mean weight-corrected PEG dose was needed in female patients (9) . It is possible that more female patients would have achieved IGF1 control in our study if a higher dose of PEG had been used from the beginning, and the maximum recommended daily dose was reached more rapidly. This effect could partially be explained by the influence of gender on the relationship between GH and IGF1 in patients with acromegaly, associated with the relative GH resistance to IGF1 generation in female patients (25) . In addition, sex differences have been found in GH-binding proteins (26, 27) to which PEG is known to bind (28) .
PEG administration was generally well tolerated, and most adverse events were self-limited and did not require specific treatment. The only serious adverse effects of PEG reported to date are tumour growth and alterations to liver function as seen for some parameters tested. In three of our patients (6.8%), a significant increase in tumour volume was associated with PEG treatment, and two patients developed hepatic dysfunction (4.5%), similar percentages to those reported previously.
It is relevant that our study confirms the ability of PEG to improve glucose metabolism under conditions of clinical practice conditions, as previously reported (8, 11, 14, 29, 30) . The acromegalic diabetic patients in our study who had been switched from SSA to PEG therapy experienced an improvement in their glucose and HbA1c levels. In addition, there was a reduction in insulin and oral hypoglycaemic drug requirements. Nevertheless, we cannot rule out previous SSA therapy as a confounding factor, since the initial evaluation was performed when patients had stopped this therapy only 4 weeks previously.
In conclusion, the results of this study indicate that long-term treatment with PEG in a clinical setting is highly effective in normalising IGF1 and improving glucose metabolism in acromegalic patients resistant to multiple therapies, including long-term SSA. The response rate is better in males and in patients who had previously received radiotherapy.
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